{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:40:10Z","timestamp":1793479210563,"version":"4.5.0"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"\n Importance<\/jats:title>\n Inhalers are the primary treatment modality for asthma and chronic obstructive pulmonary disease (COPD). Metered-dose inhalers contain hydrofluoroalkane propellants that contribute to substantial greenhouse gas emissions. The US federal government is facilitating a phasedown of hydrofluorocarbons over the next decade under international treaty obligations, yet current understanding of the scope and trajectory of inhaler-related emissions in the US remains incomplete.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To quantify the magnitude, sources, and social costs of inhaler-related emissions in the US from 2014 to 2024.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Cohort<\/jats:title>\n This serial cross-sectional analysis estimated emissions from all inhalers approved for asthma or COPD using aggregated dispensing data across the US outpatient pharmaceutical market linked to estimated greenhouse gas emissions by inhaler.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n All products were characterized based on their active pharmaceutical ingredients, device type, propellant type, therapeutic class, branded status, manufacturer, payer, and pharmacy benefit manager.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n Key end points included product utilization, greenhouse gas emissions (measured in carbon dioxide equivalents [CO\n 2<\/jats:sub>\n e] based on previously validated studies), and the social costs of emissions, which account for the net harms to society from greenhouse gases.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 1.6 billion inhalers were dispensed in the US from 2014 to 2024, generating an estimated 24.9 million metric tons of CO\n 2<\/jats:sub>\n e (mtCO\n 2<\/jats:sub>\n e). Annual emissions increased by 24% from 1.9 million mtCO\n 2<\/jats:sub>\n e in 2014 to 2.3 million mtCO\n 2<\/jats:sub>\n e in 2024. Metered-dose inhalers were responsible for 98% of all emissions during the study period, and emissions were heavily concentrated among short-acting \u03b2-agonist, inhaled corticosteroid\u2013long-acting \u03b2-agonist, and inhaled corticosteroid classes. Albuterol, budesonide-formoterol, and fluticasone propionate inhalers accounted for 87% of total emissions. The estimated social costs of emissions were $5.7 billion (lower bound, $3.5 billion; upper bound, $10.0 billion).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Inhaler-related emissions in the US have increased over the past decade. Policymakers and regulators seeking to reduce emissions should identify targeted solutions aimed at shifting utilization to currently marketed dry powder and soft mist inhalers while facilitating the entry of newer, affordable metered-dose products containing propellants with low global warming potential.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2025.16524","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T15:00:33Z","timestamp":1759762833000},"page":"1638","source":"Crossref","is-referenced-by-count":20,"title":["Inhaler-Related Greenhouse Gas Emissions in the US"],"prefix":"10.1001","volume":"334","author":[{"given":"William B.","family":"Feldman","sequence":"first","affiliation":[{"name":"Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Now with Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihye","family":"Han","sequence":"additional","affiliation":[{"name":"Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J. N.","family":"Raymakers","sequence":"additional","affiliation":[{"name":"Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg L.","family":"Furie","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian B.","family":"Chesebro","sequence":"additional","affiliation":[{"name":"Providence Center for Environmental Stewardship, Providence Health & Services, Renton, Washington"},{"name":"Department of Anesthesiology and Perioperative Medicine, Portland Veterans Affairs Medical Center, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"joi250073r4","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1513\/AnnalsATS.202202-131VP","article-title":"Small devices, big problems: addressing the global warming potential of metered-dose inhalers.","volume":"19","author":"Rabin","year":"2022","journal-title":"Ann Am Thorac Soc"},{"issue":"9","key":"joi250073r5","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMp2412383","article-title":"The moral injury of inhaler prescribing.","volume":"392","author":"Feldman","year":"2025","journal-title":"N Engl J Med"},{"issue":"23","key":"joi250073r6","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1001\/jama.2025.5942","article-title":"Reducing inhaler-related greenhouse gas emissions.","volume":"333","author":"Alkhunaizi","year":"2025","journal-title":"JAMA"},{"issue":"2","key":"joi250073r7","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1016\/S2542-5196(20)30271-0","article-title":"Health care\u2019s response to climate change: a carbon footprint assessment of the NHS in England.","volume":"5","author":"Tennison","year":"2021","journal-title":"Lancet Planet Health"},{"issue":"12","key":"joi250073r8","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1001\/jama.2024.15331","article-title":"Greenhouse gas emissions and costs of inhaler devices in the US.","volume":"332","author":"Tirumalasetty","year":"2024","journal-title":"JAMA"},{"issue":"6","key":"joi250073r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.0626","article-title":"Estimating rebates and other discounts received by Medicare Part D.","volume":"2","author":"Feldman","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"3","key":"joi250073r11","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1513\/AnnalsATS.202008-1082RL","article-title":"Trends in Medicare Part D inhaler spending: 2012-2018.","volume":"18","author":"Feldman","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"8","key":"joi250073r13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"6","key":"joi250073r17","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1111\/jcpt.13426","article-title":"Understanding authorized generics\u2014a review of the published clinical data.","volume":"46","author":"Alderfer","year":"2021","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"joi250073r18","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1377\/hlthaff.2022.01677","article-title":"Authorized generics in the US: prevalence, characteristics, and timing, 2010-19.","volume":"42","author":"Fowler","year":"2023","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"joi250073r19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/thoraxjnl-2019-213744","article-title":"Carbon footprint impact of the choice of inhalers for asthma and COPD.","volume":"75","author":"Janson","year":"2020","journal-title":"Thorax"},{"issue":"9","key":"joi250073r20","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1007\/s12325-019-01028-y","article-title":"Reduced environmental impact of the reusable Respimat soft mist inhaler compared with pressurised metered-dose inhalers.","volume":"36","author":"H\u00e4nsel","year":"2019","journal-title":"Adv Ther"},{"key":"joi250073r23","first-page":"A6315","article-title":"An assessment of pressurized metered-dose inhaler use in countries in Europe and the rest of the world.","volume":"207","author":"Bell","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"joi250073r26","doi-asserted-by":"publisher","first-page":"999","DOI":"10.5588\/ijtld.22.0483","article-title":"Global asthma report 2022: a wake-up call to enhance care and treatment for asthma globally.","volume":"26","author":"Chakaya","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"key":"joi250073r27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069679","article-title":"Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019.","volume":"378","author":"Safiri","year":"2022","journal-title":"BMJ"},{"issue":"5","key":"joi250073r28","article-title":"Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma.","volume":"5","author":"Crossingham","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"joi250073r34","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1001\/jamainternmed.2015.1665","article-title":"The impact of the US Food and Drug Administration chlorofluorocarbon ban on out-of-pocket costs and use of albuterol inhalers among individuals with asthma.","volume":"175","author":"Jena","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"6","key":"joi250073r35","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1377\/hlthaff.2021.01874","article-title":"Patents and regulatory exclusivities on inhalers for asthma and COPD, 1986-2020.","volume":"41","author":"Feldman","year":"2022","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"joi250073r36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1001\/jama.2022.19691","article-title":"Manufacturer revenue on inhalers after expiration of primary patents, 2000-2021.","volume":"329","author":"Feldman","year":"2023","journal-title":"JAMA"},{"issue":"13","key":"joi250073r37","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1056\/NEJMp2208613","article-title":"Product hopping in the drug industry\u2014lessons from albuterol.","volume":"387","author":"Wouters","year":"2022","journal-title":"N Engl J Med"},{"key":"joi250073r43","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080409","article-title":"Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study.","volume":"387","author":"Feldman","year":"2024","journal-title":"BMJ"},{"issue":"5","key":"joi250073r44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004596","article-title":"The comparative effectiveness and safety of fluticasone-salmeterol via metered-dose versus dry powder inhalers for COPD: a new user cohort study.","volume":"22","author":"Demkowicz","year":"2025","journal-title":"PLoS Med"},{"issue":"8","key":"joi250073r45","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1001\/jamainternmed.2025.2299","article-title":"Budesonide-formoterol metered-dose inhaler vs fluticasone-salmeterol dry-powder inhaler.","volume":"185","author":"Rabin","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"23","key":"joi250073r47","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMp2115675","article-title":"Decarbonizing the US health sector\u2014a call to action.","volume":"385","author":"Dzau","year":"2021","journal-title":"N Engl J Med"},{"key":"joi250073r1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. 2025 GOLD Report. Accessed August 18, 2025. https:\/\/goldcopd.org\/2025-gold-report\/"},{"key":"joi250073r2","unstructured":"Global Initiative for Asthma. Reports. Accessed August 18, 2025. https:\/\/ginasthma.org\/reports\/"},{"key":"joi250073r3","unstructured":"American Lung Association. How to use asthma medicine devices. Accessed August 18, 2025. https:\/\/www.lung.org\/lung-health-diseases\/lung-disease-lookup\/asthma\/treatment\/devices"},{"key":"joi250073r9","unstructured":"US Environmental Protection Agency. Market characterization of the US metered dose inhaler industry. Accessed August 18, 2025. https:\/\/www.epa.gov\/sites\/default\/files\/2021-03\/documents\/epa-hq-oar-2021-0044-0002_attachment_1-mdis.pdf"},{"key":"joi250073r12","unstructured":"United Nations Environmental Programme. About Montreal Protocol. Accessed August 18, 2025. https:\/\/www.unep.org\/ozonaction\/who-we-are\/about-montreal-protocol"},{"key":"joi250073r14","unstructured":"Symphony Health. Metys database. Accessed August 18, 2025. https:\/\/www.iconplc.com\/solutions\/symphony-health\/health-technology-and-business-intelligence-solutions"},{"key":"joi250073r15","unstructured":"US Food and Drug Administration. Drugs@FDA: FDA-approved drugs. Accessed August 18, 2025. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm"},{"key":"joi250073r16","unstructured":"US Food and Drug Administration. FDA list of authorized generics. Accessed August 18, 2025. https:\/\/www.fda.gov\/drugs\/abbreviated-new-drug-application-anda\/fda-list-authorized-generic-drugs"},{"key":"joi250073r21","unstructured":"US Environmental Protection Agency. Report on the social cost of greenhouse gases: estimates incorporating recent scientific advances. Accessed August 18, 2025. https:\/\/www.epa.gov\/system\/files\/documents\/2023-12\/epa_scghg_2023_report_final.pdf"},{"key":"joi250073r22","unstructured":"US Bureau of Labor and Statistics. Consumer Price Index for All Urban Consumers (CPI-U). Accessed August 18, 2025. https:\/\/www.bls.gov\/cpi\/"},{"key":"joi250073r24","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Accessed August 18, 2025. https:\/\/www.R-project.org\/"},{"key":"joi250073r25","unstructured":"US Environmental Protection Agency. Greenhouse gas equivalencies calculator. Accessed August 18, 2025. https:\/\/www.epa.gov\/energy\/greenhouse-gas-equivalencies-calculator"},{"key":"joi250073r29","unstructured":"Electronic Medicines Compendium. Symbicort Turbohaler 200\/6 inhalation powder. Accessed August 18, 2025. https:\/\/www.medicines.org.uk\/emc\/product\/1327\/smpc#gref"},{"key":"joi250073r30","unstructured":"European Medicines Agency. DuoResp Spiromax. Accessed August 18, 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/duoresp-spiromax"},{"key":"joi250073r31","unstructured":"GSK. GSK announces major step towards sustainability ambitions with advancement of low carbon Ventolin programme to phase III trials. Accessed August 18, 2025. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-announces-major-step-towards-sustainability-ambitions-with-advancement-of-low-carbon-ventolin-programme-to-phase-iii-trials\/"},{"key":"joi250073r32","unstructured":"AstraZeneca. AstraZeneca announces the completion of the clinical programme to support the transition of Breztri to next-generation propellant with near-zero global warming potential. Accessed August 18, 2025. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2024\/astrazeneca-announces-the-completion-of-the-clinical-programme-to-support-the-transition-of-breztri-to-next-generation-propellant-with-near-zero-global-warming-potential.html"},{"key":"joi250073r33","unstructured":"AstraZeneca. Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation propellant with near-zero global warming potential. Accessed August 18, 2025. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/trixeo-aerosphere-approved-in-the-uk-as-first-inhaled-respiratory-medicine-using-next-generation-propellant-with-near-zero-global-warming-potential.html"},{"key":"joi250073r38","unstructured":"Center for Research on Complex Generics. Navigating the transition to low global warming potential propellants. Accessed August 18, 2025. https:\/\/www.complexgenerics.org\/education-training\/navigating-the-transition-to-low-global-warming-potential-propellants\/"},{"key":"joi250073r39","unstructured":"IQVIA. The use of medicines in the US 2024: usage and spending trends and outlook to 2028. Accessed August 18, 2025. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/the-use-of-medicines-in-the-us-2024"},{"key":"joi250073r40","unstructured":"US Department of Veterans Affairs. Pharmacy benefits management services. Accessed August 18, 2025. https:\/\/www.pbm.va.gov\/pbm\/cmop\/va_mail_order_pharmacy.asp"},{"key":"joi250073r41","unstructured":"US Department of Veterans Affairs. Automated pharmacy means more veterans get prescriptions faster. Accessed August 18, 2025. https:\/\/news.va.gov\/133691\/automated-pharmacy-veterans-get-prescriptions"},{"key":"joi250073r42","unstructured":"US Defense Health Agency. TRICARE by the numbers. Accessed August 18, 2025. https:\/\/dha.mil\/About-DHA\/TRICARE-Numbers"},{"key":"joi250073r46","unstructured":"US Environmental Protection Agency. Sources of greenhouse gas emissions. Accessed August 18, 2025. https:\/\/www.epa.gov\/ghgemissions\/sources-greenhouse-gas-emissions"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2839471\/jama_feldman_2025_oi_250073_1761928743.07245.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:00:44Z","timestamp":1762876844000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2839471"}},"subtitle":["A Serial Cross-Sectional Analysis"],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":47,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.16524","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,11]]}}}